<i>In vivo</i> delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates-Reference-Cited by-同舟云学术

In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates

Published:2024-01-02 Issue: Volume: Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Patel Ami¹,Rosenke Kyle²,Parzych Elizabeth M.¹,Feldmann Friederike²,Bharti Suman¹,Griffin Amanda J.²,Schouest Blake³,Lewis Matt²,Choi Jihae¹,Chokkalingam Neethu¹,Machado Viviane³,Smith Brian J.²,Frase Drew¹,Ali Ali R.¹,Lovaglio Jamie²,Nguyen Brian³,Hanley Patrick W.²,Walker Susanne N.¹,Gary Ebony N.¹,Kulkarni Abhijeet¹,Generotti Allison³,Francica Joseph R.⁴,Rosenthal Kim⁴,Kulp Daniel W.¹,Esser Mark T⁴,Smith Trevor R.F.³,Shaia Carl²^ORCID,Weiner David B¹,Feldmann Heinz²^ORCID

Affiliation:

1. Vaccine and Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, PA, USA

2. Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

3. Inovio Pharmaceuticals, Plymouth Meeting, PA, USA

4. Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Funder

Defense Sciences Office, DARPA

National Institutes of Health

The Jill and Mark Fishman Foundation

W. W. Smith Charitable Trust

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2023.2294860

Reference41 articles.

1. An interactive web-based dashboard to track COVID-19 in real time

2. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

3. CDC. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed September 2022.

4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

5. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant